Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Sanderson

Showing results (261-270 of 387) with videos related to

Pageof 39
Sort By:
Molecular Immunology|August 7, 2007
The role of complement in innate, adaptive and eosinophil-dependent immunity to the nematode Nippostrongylus brasiliensisPaul R Giacomin, David L Gordon, Marina Botto, et al.
Microbial Genomics|February 7, 2023
Comparison of R9.4.1/Kit10 and R10/Kit12 Oxford Nanopore flowcells and chemistries in bacterial genome reconstructionNicholas D Sanderson, Natalia Kapel, Gillian Rodger, et al.
The Journal of Peptide Research : Official Journal of the American Peptide Society|April 9, 1999
The influence of Lys68 in decepeptide agonists of C5a on C5a receptor binding, activation and selectivityS M Vogen, A M Finch, S K Wadi, et al.
The FEBS Journal|February 5, 2013
The heparanase/syndecan-1 axis in cancer: mechanisms and therapiesVishnu C Ramani, Anurag Purushothaman, Mark D Stewart, et al.
Blood|October 26, 2000
High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activityC Seidel, M Børset, O Hjertner, et al.
Gut|June 22, 2002
Related IgA1 and IgG producing cells in blood and diseased mucosa in ulcerative colitisV C Thoree, S J C Golby, L Boursier, et al.
The Journal of Biological Chemistry|September 30, 2005
HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivoYuemeng Dai, Yang Yang, Veronica MacLeod, et al.
Alimentary Pharmacology & Therapeutics|June 9, 2009
Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel diseaseM A Smith, A M Marinaki, M Arenas, et al.
Inflammation|June 14, 2001
Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytesT M Woodruff, A J Strachan, S D Sanderson, et al.
The Journal of Biological Chemistry|June 10, 1994
Influence of acceptor substrate primary amino acid sequence on the activity of human UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase. Studies with the MUC1 tandem repeatI Nishimori, N R Johnson, S D Sanderson, et al.
Pageof 39

Showing results (261-270 of 387) with videos related to

Sort By:
Pageof 39
Molecular Immunology|August 7, 2007
The role of complement in innate, adaptive and eosinophil-dependent immunity to the nematode Nippostrongylus brasiliensisPaul R Giacomin, David L Gordon, Marina Botto, et al.
Microbial Genomics|February 7, 2023
Comparison of R9.4.1/Kit10 and R10/Kit12 Oxford Nanopore flowcells and chemistries in bacterial genome reconstructionNicholas D Sanderson, Natalia Kapel, Gillian Rodger, et al.
The Journal of Peptide Research : Official Journal of the American Peptide Society|April 9, 1999
The influence of Lys68 in decepeptide agonists of C5a on C5a receptor binding, activation and selectivityS M Vogen, A M Finch, S K Wadi, et al.
The FEBS Journal|February 5, 2013
The heparanase/syndecan-1 axis in cancer: mechanisms and therapiesVishnu C Ramani, Anurag Purushothaman, Mark D Stewart, et al.
Blood|October 26, 2000
High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activityC Seidel, M Børset, O Hjertner, et al.
Gut|June 22, 2002
Related IgA1 and IgG producing cells in blood and diseased mucosa in ulcerative colitisV C Thoree, S J C Golby, L Boursier, et al.
The Journal of Biological Chemistry|September 30, 2005
HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivoYuemeng Dai, Yang Yang, Veronica MacLeod, et al.
Alimentary Pharmacology & Therapeutics|June 9, 2009
Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel diseaseM A Smith, A M Marinaki, M Arenas, et al.
Inflammation|June 14, 2001
Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytesT M Woodruff, A J Strachan, S D Sanderson, et al.
The Journal of Biological Chemistry|June 10, 1994
Influence of acceptor substrate primary amino acid sequence on the activity of human UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase. Studies with the MUC1 tandem repeatI Nishimori, N R Johnson, S D Sanderson, et al.
Pageof 39